All Federal Grant Awards
Help

Project Grant R44DA056277

Award Date 9/30/22
Completion Date 5/31/28
Dollars Obligated $2.1M
Federal Agency
National Institute on Drug Abuse
Awardee
Rescue Biomedical, LLC (J8QBJPND4RJ3)
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
West Lafayette, IN, USA
Similar Awards
Project Grant R43DA063255
Logo for National Institute on Drug Abuse (HHS - NIH)
This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $399,715 to Rescue Biomedical, LLC to develop and commercialize the Automatic Detection Device (AD2) component of their Automatic Antidote Delivery Device (A2D2). The AD2 is a user-centric wearable device that can automatically detect opioid overdose and alert emergency services, with the goal of reducing opioid overdose-related deaths. The key...
Project Grant R44DA060643
Logo for National Institute on Drug Abuse (HHS - NIH)
The National Institute on Drug Abuse (NIDA) awarded Resilient Lifescience, Inc. a $854,122 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop a wearable medical device that can detect opioid-induced respiratory depression and issue an emergency alert. The goal is to create a technology solution that can help ensure rapid administration of the life-saving drug naloxone when an opioid overdose occurs, particularly in situations where the individual is...
Cooperative Agreement U44DA061027
Logo for National Institute on Drug Abuse (HHS - NIH)
This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is funding the development of ODALERT - an innovative wearable device designed to detect and alert users and first responders of potential opioid overdoses. The $800,000 award to Biosensics LLC, a digital health technology company, will support the completion of ODALERT's sensor development, optimization of battery life, deployment of real-time...
Project Grant 2335577
Logo for National Science Foundation
The National Science Foundation (NSF) awarded a Project Grant under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Resilient Lifescience, Inc. for the development and validation of a novel wearable medical device to detect and treat opioid overdose. The $274,964 award, effective March 15, 2024 through December 31, 2024, will fund the development of two key components: 1) a self-contained, patch-based drug delivery platform capable of reliably delivering multiple...
Project Grant R33DA062346
Logo for National Institute on Drug Abuse (HHS - NIH)
This Project Grant award of $2,316,128.00 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to design tailored harm reduction strategies to address the opioid overdose crisis across six distinct jurisdictions. The project, titled "REVERSING OVERDOSE EPIDEMICS THROUGH SIMULATION, COLLABORATION, AND UNIFIED EFFORTS (RESCUE)", will collaborate with health departments and community partners to assess the...
Project Grant R43DA060696
Logo for National Institute on Drug Abuse (HHS - NIH)
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is supporting the development of a software-based medical device (SAMD) for detecting opioid use through voice analysis. The $800,000 award to Tenvos Inc., a minority-owned and woman-owned technology company, aims to advance the company's AI-driven solution that can enable patients to remotely test for opioid use and securely share results with...
Cooperative Agreement U01DA059791
Logo for National Institute on Drug Abuse (HHS - NIH)
The National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), has awarded a $23,579,701 Cooperative Agreement to Ensysce Biosciences, Inc. to support the clinical development of PF614-MPAR, an opioid product with oral overdose protection. The key objectives of this project are to continue the clinical development of PF614-MPAR, a combination product of a trypsin-activated abuse protection (TAAP) oxycodone prodrug and a trypsin inhibitor...
Project Grant R43DA060717
Logo for National Institute on Drug Abuse (HHS - NIH)
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $598,312 to Addinex Technologies, Inc. to integrate and assess the practicality of a closed-loop medication management system for opioid pain management targeting ambulatory patients with extremity fractures being discharged from the emergency department. The key objectives are to adapt the Addinex system to seamlessly integrate with hospital...
Project Grant R43DA061397
Logo for National Institute on Drug Abuse (HHS - NIH)
The National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), awarded Labsys LLC a $643,948 Project Grant to develop a wearable continuous drug monitoring device for opioid use disorders (CDM-MOUD). The goal is to create a low-cost, pain-free patch that can monitor medication levels in the interstitial fluid and provide real-time insights into the effectiveness of opioid use disorder treatment protocols. In Phase I, Labsys will engineer an...
Project Grant R42DA062250
Logo for National Institute on Drug Abuse (HHS - NIH)
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $400,000 to Mountainpass Technology LLC to develop, refine, and evaluate a customized version of their "MyTrials" integrated remote biomarker capture system for decentralized clinical trials (DCTs) focused on substance use disorders (SUDs). The project aims to address key methodological limitations of DCTs for SUDs by creating a product...

USER-CENTRIC DEVELOPMENT OF CLOSED-LOOP THERAPY FOR OPIOID OVERDOSE - PROJECT SUMMARY/ABSTRACT THIS FAST-TRACK SBIR PROPOSAL WILL HELP MAKE SIGNIFICANT INROADS TOWARDS COMMERCIALIZING RESCUE BIOMEDICAL LLC'S AUTOMATIC ANTIDOTE DELIVERY DEVICE (A2D2) IN ORDER TO COMBAT OPIOID OVERDOSE-RELATED DEATHS. DESPITE INCREASING AWARENESS OF THE DANGERS ASSOCIATED WITH OPIOIDS, THERE WERE MORE THAN 70,000 DEATHS DUE TO OPIOID OVERDOSE IN 2020. IN ADDITION, THE RISING POPULARITY OF ILLEGAL SYNTHETIC OPIOIDS AND SOCIAL ISOLATION DUE TO THE ONGOING COVID-19 PANDEMIC IS FUELING A THIRD WAVE OF OPIOID-RELATED DEATHS. SINCE THESE ILLEGAL DRUGS ARE ORDERS OF MAGNITUDE MORE POTENT THAN MORPHINE AND CAN CAUSE RESPIRATORY FAILURE IN MINUTES, THERE IS VERY LITTLE TIME FOR USERS TO IDENTIFY AND RESPOND TO THE SYMPTOMS OF OVERDOSE WITH ANTIDOTES LIKE NALOXONE. THE PROPOSED A2D2 IS A LOW-COST AND SIMPLE SUBCUTANEOUS DRUG DELIVERY CAPSULE THAT CAN AUTOMATICALLY DETECT OPIOID- INDUCED RESPIRATORY FAILURE AND RELEASE NALOXONE IN A CLOSED-LOOP MANNER. IT WILL EXTEND THE LIFETIME OF OVERDOSED PATIENTS SO THAT THEY CAN RECEIVE PROPER MEDICAL CARE. IN THIS FAST-TRACK SBIR PROPOSAL, RESCUE BIOMEDICAL SEEKS TO VALIDATE ITS HYPOTHESIS THAT THERE IS A SIGNIFICANT DEMAND FOR A WEARABLE-IMPLANTABLE COMBINATIONAL DEVICE FOR AUTOMATICALLY DETECTING AND TREATING OPIOID OVERDOSE. IN PHASE I, RESCUE BIOMEDICAL WILL WORK WITH ITS COLLABORATOR AT INDIANA UNIVERSITY SCHOOL OF MEDICINE TO QUANTIFY USERS' WILLINGNESS TO USE WEARABLE AND IMPLANTABLE DEVICES. FURTHERMORE, CLINICIANS AND OTHER STAKEHOLDERS (E.G., LICENSED CHEMICAL DEPENDENCY COUNSELOR) WILL BE IDENTIFIED TO UNDERSTAND THEIR WILLINGNESS TO RECOMMEND ADVANCED HARM REDUCTION DEVICES. FINALLY, RESCUE BIOMEDICAL WILL LEVERAGE THE COHORT OF THESE STAKEHOLDERS TO VALIDATE THE OVERALL SYSTEM DESIGN TO ENSURE HIGH COMPLIANCE AND USABILITY. IN PHASE II, EFFORTS WILL BE FOCUSED ON TECHNICAL INTEGRATION AND PERFORMING A PIVOTAL PRE-CLINICAL EXPERIMENT TO DEMONSTRATE THE CLOSED-LOOP CAPABILITIES TO REVERSE THE EFFECTS OF OPIOID OVERDOSE. MOREOVER, RESCUE BIOMEDICAL WILL FOCUS EFFORTS FOR COMMERCIALIZATION INCLUDING REGULATORY SUBMISSIONS FOR IND/IDE SUBMISSION AND PERFORMING DESIGN VERIFICATION AND VALIDATION BASED ON USER FEEDBACK.

Posted 9/21/22